Project Grant R21HL182127
- This Project Grant award, valued at $733,439.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The grant supports research to define the molecular triggers and consequences of CART signaling in aortic smooth muscle cells, and determine the role of sexually dimorphic signaling mechanisms in thoracic aortic aneurysm (TAA) pathogenesis. The research aims to advance the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a $771,485 research project titled "CAROTID-MAP CAROTID ATHEROSCLEROTIC RISK ASSESSMENT THROUGH IMAGING ANDPREDICTION". The project aims to develop reliable imaging-derived markers in carotid artery computed tomography angiography (CTA) scans to identify high-risk plaque features associated with cryptogenic stroke. The research...
- This $722,299 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research initiative to use deep learning techniques to study normal variation in aortic valve hemodynamics and its link to the development of aortic stenosis. The primary objectives are to: 1) Measure aortic valve parameters in 100,000 UK Biobank participants using deep learning models, validate the measurements at UCSF, and develop models to identify...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $410,139.00 to the University of Pittsburgh to advance the development of a novel density-driven strength assessment tool for predicting the risk of thoracic aortic aneurysm (TAA) rupture or dissection. The project aims to: Assess the relationship between TAA tissue density and local tissue strength, and Evaluate the use of diffusion tensor magnetic...
- The University of Cincinnati, through its Sponsored Research Services Division, was awarded a $156,276 project grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on "Hematopoietic Cells and Chemokine Regulation in Abdominal Aortic Aneurysm Associated Thrombosis". The project, with a performance period from August 1, 2025 to June 30, 2027, aims to investigate the role of platelet activation and...
- This federal Project Grant award of $174,528, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to identify novel treatment targets for atrial myopathy, a condition that contributes to atrial fibrillation and associated heart failure, stroke, and mortality. The primary objective is to leverage human cohort data to discover circulating proteins and metabolites linked to both left atrial function and atrial myopathy, using...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $164,127 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Texas Health Science Center at Houston (UTHealth) to develop an artificial intelligence-based facial recognition tool for screening and early detection of heritable thoracic aortic disease (HTAD). The project aims to leverage facial image data from the Montalcino Aortic Consortium's patient registry to build a...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,182,618 to Iowa State University of Science and Technology to develop an advanced "digital twin" technology for personalized cardiovascular care. The goal is to create a rapid, predictive modeling platform that can simulate heart valve disease progression and optimize long-term treatment interventions. The research aims to integrate scientific machine...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds a study to investigate the molecular mechanisms linking atrial cardiopathy to cardiovascular disease outcomes. The $1,657,473 award, granted on September 24, 2025, supports the use of proteomic and genomic methods in two diverse populations - individuals free of clinically recognized cardiovascular disease and patients with recent...
- This $713,382 Project Grant award from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Pennsylvania on the role of triglyceride-rich lipoproteins in the growth and progression of abdominal aortic aneurysms. The research aims to generate definitive causal evidence on how triglyceride-rich lipoproteins influence the development, growth, and rupture of these life-threatening aortic aneurysms, with the goal...
The Regents of the University of Minnesota was awarded a $389,748 project grant from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a proof-of-concept study on using carotid pulse arrival time (CPAT) as a potential biomarker for monitoring ascending thoracic aortic aneurysm. The grant will fund experiments to determine if CPAT can reliably measure population-level trends in pulse wave velocity, as well as computer simulations of fluid-structure interaction flow in the ascending aorta using patient scan data. The project aims to assess whether CPAT, which can be easily measured via surface tonometry or electrical impedance, could serve as a less expensive and more accessible alternative to contrast CT scans for routine monitoring of aortic aneurysm, especially for patients in rural areas. The award period runs from August 15, 2025 to July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $389.7k | 8/9/25 |